Biopsy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

A biopsy is a diagnostic procedure in which a small sample of living tissue is removed from the body and examined under a microscope by a pathologist. It is the definitive method to diagnose cancer, chronic infection, inflammatory disease, or other tissue abnormalities that cannot be distinguished by clinical examination or imaging alone. The word biopsy derives from the Greek bios (life) and opsis (vision). Tissue samples are processed through fixation in formalin, embedding in paraffin wax, slicing to 3–5 microns, and staining with haematoxylin and eosin (H&E), with additional immunohistochemical stains as required. Advanced molecular techniques — next-generation sequencing, FISH, PCR — can be applied to biopsy material to identify specific gene mutations guiding targeted therapy selection. There are multiple biopsy techniques, each suited to different anatomical sites and clinical situations. The choice of technique balances diagnostic yield against risk of complications, patient comfort, and available guidance modalities including ultrasound and CT. A biopsy is a diagnostic procedure in which a sample of living tissue is removed from the body and examined microscopically by a pathologist to determine whether a lesion is benign, malignant, or inflammatory. Biopsy is considered the definitive gold-standard investigation for cancer diagnosis — imaging findings, tumour markers, and clinical examination alone cannot confirm malignancy with sufficient certainty to guide treatment. Multiple biopsy techniques exist, ranging from minimally invasive fine needle aspiration to surgical open excisional biopsy. Image-guided core needle biopsies performed under ultrasound, CT, or MRI guidance are now the most commonly performed technique for accessible internal lesions. Biopsies are performed by interventional radiologists, surgeons, gastroenterologists, pulmonologists, dermatologists, and pathologists depending on the lesion location. Pathological interpretation includes histology (tissue architecture), immunohistochemistry (IHC), and increasingly molecular genomic profiling to characterise tumour biology and guide targeted therapy selection.

Biopsy is indicated when imaging or blood tests suggest cancer, infection, or inflammatory disease requiring histological confirmation before treatment is commenced. Any palpable lump, mass, or abnormal lesion detected on imaging that cannot be confidently characterised as benign warrants tissue sampling. Common clinical scenarios include a breast mass, thyroid nodule above 1 cm, lung lesion on CT, liver lesion, enlarged lymph node, suspicious skin lesion, unexplained weight loss with abdominal masses, or abnormal bone marrow findings. Biopsy is also performed to diagnose autoimmune conditions such as vasculitis or inflammatory myopathy, chronic liver disease (grading fibrosis), and kidney disease (characterising glomerulonephritis). Prostate biopsy is performed for PSA elevation or abnormal digital rectal examination. Endometrial biopsy investigates abnormal uterine bleeding. In established malignancy, repeat biopsy at disease progression identifies resistance mutations guiding second-line therapy selection.

The biopsy technique depends on lesion location, size, and accessibility. Fine needle aspiration (FNA) uses a 22–25 gauge needle to aspirate cells from superficial or image-accessible lesions for cytological analysis; it is rapid and minimally invasive but provides cells rather than tissue architecture. Core needle biopsy (CNB) uses a 14–18 gauge spring-loaded needle to extract cylindrical tissue cores 15–20 mm long, providing architecture for histological diagnosis with sensitivity of 90–99% for most solid tumours. Both FNA and CNB use ultrasound, CT, or endoscopic ultrasound guidance for deep lesions. Punch biopsy removes a 2–6 mm skin disc using a circular blade under local anaesthesia. Excision biopsy surgically removes the entire lesion for complete pathological assessment. Endoscopic biopsy uses flexible endoscopes (gastroscopy, colonoscopy, bronchoscopy) to take multiple small samples from mucosal lesions. Liquid biopsy analyses circulating tumour DNA from peripheral blood — a non-invasive emerging technique for certain cancers. Results typically return in 5–10 working days. The biopsy technique depends on lesion location, size, and accessibility. Fine needle aspiration (FNA) uses a 22–25 gauge needle to aspirate cells from superficial or image-accessible lesions for cytological examination, without an anaesthetic requirement. Core needle biopsy uses a spring-loaded biopsy gun (14–18 gauge) to retrieve cylindrical tissue cores 1–2 cm long under local anaesthesia, providing histological (architectural) analysis — the standard for solid organ and breast lesions. Vacuum-assisted biopsy devices use suction to retrieve larger tissue volumes from a single insertion site. Sentinel lymph node biopsy uses radiotracer and blue dye injection to identify and sample the first-echelon draining lymph node in cancer staging. Endoscopic biopsies are taken during colonoscopy, gastroscopy, or bronchoscopy using forceps passed through the working channel. Open surgical biopsy (incisional or excisional) is reserved for lesions inaccessible to image-guided biopsy. Specimen handling includes fixation in formalin for histology or fresh transport for culture, flow cytometry, or molecular analysis.

Biopsy provides the highest level of diagnostic accuracy available in clinical medicine, forming the foundation of cancer diagnosis worldwide. Core needle biopsy achieves 90–99% sensitivity for breast, liver, kidney, and lung cancers in experienced hands. Fine needle aspiration sensitivity varies by site: 85–95% for thyroid, lymph nodes, and salivary glands. Biopsy results determine the exact tumour type, grade, and molecular subtype — information that directly determines whether surgery, chemotherapy, radiotherapy, hormonal therapy, or immunotherapy is appropriate. In non-oncological settings, kidney biopsy defines glomerular disease type with therapeutic consequences; liver biopsy accurately stages fibrosis; temporal artery biopsy confirms giant cell arteritis. The benefits of definitive diagnosis far outweigh the small procedure-related risks in virtually all clinical situations. Negative biopsy results in a low-risk patient can avoid unnecessary surgery or treatment, providing significant reassurance.

Biopsy is generally safe with low complication rates that vary by technique and anatomical site. Common minor complications include pain, bruising, and local haematoma at the biopsy site, which resolve within a few days and are managed with simple analgesics. Infection at the biopsy site is uncommon (under 1%) with aseptic technique. Superficial biopsies (skin, breast) carry very low risk. Deep biopsies carry site-specific risks: lung biopsy carries a 15–20% pneumothorax rate (most resolve spontaneously); liver biopsy has a 0.3% risk of significant bleeding; kidney biopsy a 1–3% risk of significant haematuria. Organ injury is rare but possible for deep lesions. Needle track seeding of cancer cells — a theoretical concern — is extremely rare, estimated at less than 1 in 20,000 procedures for most tumours and does not affect overall survival. Patients on anticoagulants require dose adjustment before biopsy. Contraindications include uncorrectable coagulopathy and inaccessible lesion position.

Recovery depends on the biopsy type and site. Most percutaneous biopsies (FNA, core needle, punch) are outpatient procedures with rapid recovery. Patients are observed for 1–2 hours after deep biopsies (liver, kidney, lung) to detect early complications. Minor bruising or soreness at the site resolves within 3–5 days. Strenuous activity is avoided for 24–48 hours, or longer (1–2 weeks) after surgical excision biopsies. Oral analgesia (paracetamol, NSAIDs unless contraindicated) manages post-procedure discomfort. The biopsy site should be kept clean and dry for 24–48 hours; dressings are changed as instructed. Wound care instructions are provided for punch and excision biopsies. Results are typically available within 5–10 working days for routine histology. Patients should contact their clinical team promptly if they develop fever, increased pain, swelling, redness at the biopsy site, or symptoms suggesting deep complications (haemoptysis, haematuria, abdominal rigidity).